BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 16828940)

  • 41. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
    Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
    Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice.
    Caulfield MJ; Shi L; Wang S; Wang B; Tobery TW; Mach H; Ahl PL; Cannon JL; Cook JC; Heinrichs JH; Sitrin RD
    Hum Vaccin; 2007; 3(4):139-45. PubMed ID: 17581283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.
    Zacharia A; Harberts E; Valencia SM; Myers B; Sanders C; Jain A; Larson NR; Middaugh CR; Picking WD; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Ernst RK; Marshall JD
    Vaccine; 2021 Jan; 39(2):292-302. PubMed ID: 33309485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
    Yan X; Wang D; Liang F; Fu L; Guo C
    Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine.
    Azimi A; Heidarian S; Zamani H; Taleghani N; Dehghani M; Seyedjafari E
    Biologicals; 2020 Nov; 68():60-64. PubMed ID: 32859464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
    J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
    Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
    Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
    Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
    Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques.
    Tobery TW; Smith JF; Kuklin N; Skulsky D; Ackerson C; Huang L; Chen L; Cook JC; McClements WL; Jansen KU
    Vaccine; 2003 Mar; 21(13-14):1539-47. PubMed ID: 12615451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
    Fraillery D; Zosso N; Nardelli-Haefliger D
    Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical development of AS04.
    Garçon N
    Methods Mol Biol; 2010; 626():15-27. PubMed ID: 20099118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
    Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
    J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.